Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RIAZ BABER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1740365808
CMS profile
169404
Location
NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$25.10

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $25.10 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
LivaNova USA, Inc. $25.10 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RIAZ BABER

NPI 1740365808 · CMS profile ID 169404

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740365808?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740365808?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740365808?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RIAZ BABER, NPI 1740365808, CMS profile ID 169404, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740365808?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $25.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LivaNova USA, Inc. $25.1006/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844255537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.48 1
PY2021 $25.10 1
PY2022 $90.37 4
PY2023 $52.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $341,122.24 185
PY2024 Principal investigator $389,598.32 164
PY2023 Recipient $20,894.00 17
PY2023 Principal investigator $262,289.24 63
PY2022 Recipient $8,539.60 3
PY2022 Principal investigator $221,491.86 60
PY2021 Recipient $40,104.00 15
PY2021 Principal investigator $235,417.23 45
PY2020 Principal investigator $547,839.81 74
PY2019 Recipient $1,141.05 5
PY2019 Principal investigator $378,637.76 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

185 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $5,099.00 12/25/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332692
Principal investigator 1 Janssen Research & Development, LLC $621.00 12/11/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332753
Principal investigator 1 PFIZER INC. $1,200.00 12/11/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228811687
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/05/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332611
Principal investigator 1 Janssen Research & Development, LLC $790.00 12/05/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332713
Principal investigator 1 Janssen Research & Development, LLC $8,267.00 12/04/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332643
Principal investigator 1 Janssen Research & Development, LLC $221.72 12/04/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332731
Principal investigator 1 Janssen Research & Development, LLC $335.56 12/01/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332604
Principal investigator 1 PFIZER INC. $2,400.00 11/24/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228817805
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,678.00 11/20/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242366241
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/17/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332761
Principal investigator 1 Vanda Pharmaceuticals Inc. $16,100.00 11/14/2025 Non-covered Recipient Entity
AMR-BABER RESEARCH
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946943
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,000.00 11/14/2025 Non-covered Recipient Entity
AMR-BABER RESEARCH
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946947
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,900.00 11/14/2025 Non-covered Recipient Entity
AMR-BABER RESEARCH
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946951
Principal investigator 1 Janssen Research & Development, LLC $1,525.00 11/12/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214464
Principal investigator 1 LivaNova USA, Inc. $687.15 11/11/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546507
Principal investigator 1 LivaNova USA, Inc. $687.15 11/11/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546512
Principal investigator 1 LivaNova USA, Inc. $687.15 11/11/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546516
Principal investigator 1 LivaNova USA, Inc. $687.15 11/11/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546519
Principal investigator 1 Janssen Research & Development, LLC $4,400.00 11/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332723
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 11/06/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242365855
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $643.00 11/06/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242365857
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,000.00 11/03/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-321 No dispute reported 06/30/2026 1242365103
Principal investigator 1 Janssen Research & Development, LLC $6,816.00 10/30/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332635
Principal investigator 1 PFIZER INC. $1,200.00 10/23/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228823120
Principal investigator 1 LivaNova USA, Inc. $1,210.95 10/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546420
Principal investigator 1 LivaNova USA, Inc. $105.30 10/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546424
Principal investigator 1 LivaNova USA, Inc. $312.41 10/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546428
Principal investigator 1 LivaNova USA, Inc. $687.15 10/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546432
Principal investigator 1 LivaNova USA, Inc. $544.05 10/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546436
Principal investigator 1 LivaNova USA, Inc. $1,210.95 10/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546494
Principal investigator 1 LivaNova USA, Inc. $105.30 10/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546499
Principal investigator 1 LivaNova USA, Inc. $687.15 10/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546502
Principal investigator 1 Janssen Research & Development, LLC $3,550.00 10/06/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214426
Principal investigator 1 Janssen Research & Development, LLC $157.86 10/03/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175332706
Principal investigator 1 Janssen Research & Development, LLC $11,414.00 09/29/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332686
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $235.00 09/22/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242359242
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,678.00 09/22/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242359244
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 09/22/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242359246
Principal investigator 1 Janssen Research & Development, LLC $445.75 09/19/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332598
Principal investigator 1 LivaNova USA, Inc. $1,124.55 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546399
Principal investigator 1 LivaNova USA, Inc. $1,210.95 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546404
Principal investigator 1 LivaNova USA, Inc. $105.30 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546407
Principal investigator 1 LivaNova USA, Inc. $36.80 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546412
Principal investigator 1 LivaNova USA, Inc. $687.15 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546416
Principal investigator 1 LivaNova USA, Inc. $1,210.95 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546475
Principal investigator 1 LivaNova USA, Inc. $1,210.95 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546478
Principal investigator 1 LivaNova USA, Inc. $105.30 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546482
Principal investigator 1 LivaNova USA, Inc. $105.30 09/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546487
Principal investigator 1 Janssen Research & Development, LLC $7,552.00 09/08/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214455
Principal investigator 1 PFIZER INC. $1,000.00 09/04/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228824084
Principal investigator 1 Janssen Research & Development, LLC $10,891.00 09/01/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332657
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,000.00 08/25/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-321 No dispute reported 06/30/2026 1242357792
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $73.59 08/20/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242357602
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,245.24 08/18/2025 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP
ACP-103-070 No dispute reported 06/30/2026 1245935529
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 08/18/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332619
Principal investigator 1 LivaNova USA, Inc. $105.30 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546442
Principal investigator 1 LivaNova USA, Inc. $105.30 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546447
Principal investigator 1 LivaNova USA, Inc. $687.15 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546454
Principal investigator 1 LivaNova USA, Inc. $687.15 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546458
Principal investigator 1 LivaNova USA, Inc. $687.15 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546462
Principal investigator 1 LivaNova USA, Inc. $687.15 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546466
Principal investigator 1 LivaNova USA, Inc. $544.05 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546470
Principal investigator 1 LivaNova USA, Inc. $1,124.55 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546819
Principal investigator 1 LivaNova USA, Inc. $750.60 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546824
Principal investigator 1 LivaNova USA, Inc. $1,210.95 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546828
Principal investigator 1 LivaNova USA, Inc. $105.30 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546831
Principal investigator 1 LivaNova USA, Inc. $200.00 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546835
Principal investigator 1 LivaNova USA, Inc. $687.15 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546840
Principal investigator 1 LivaNova USA, Inc. $544.05 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546843
Principal investigator 1 LivaNova USA, Inc. $1,124.55 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546916
Principal investigator 1 LivaNova USA, Inc. $1,210.95 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546920
Principal investigator 1 LivaNova USA, Inc. $1,210.95 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546924
Principal investigator 1 LivaNova USA, Inc. $1,210.95 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546928
Principal investigator 1 LivaNova USA, Inc. $1,210.95 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546932
Principal investigator 1 LivaNova USA, Inc. $1,210.95 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546935
Principal investigator 1 LivaNova USA, Inc. $105.30 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546939
Principal investigator 1 LivaNova USA, Inc. $105.30 08/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546942
Principal investigator 1 PFIZER INC. $1,056.37 07/29/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228841623
Principal investigator 1 LivaNova USA, Inc. $1,345.00 07/22/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556907
Principal investigator 1 Janssen Research & Development, LLC $1,808.00 07/11/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214471
Principal investigator 1 Janssen Research & Development, LLC $1,735.00 07/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332628
Principal investigator 1 Janssen Research & Development, LLC $8,450.00 07/09/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214433
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,600.00 07/07/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242352528
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,052.00 07/07/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242352530
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,100.00 07/07/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242352532
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,037.00 07/07/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242352534
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,033.00 07/07/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242352536
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,528.00 06/25/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242352166
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,436.00 06/25/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242352168
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 06/25/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242352184
Principal investigator 1 LivaNova USA, Inc. $90.00 06/17/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556850
Principal investigator 1 Janssen Research & Development, LLC $1,275.00 06/13/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214447
Principal investigator 1 LivaNova USA, Inc. $1,124.55 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546643
Principal investigator 1 LivaNova USA, Inc. $1,210.95 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546648
Principal investigator 1 LivaNova USA, Inc. $105.30 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546651
Principal investigator 1 LivaNova USA, Inc. $687.15 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546658
Principal investigator 1 LivaNova USA, Inc. $544.05 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546661
Principal investigator 1 LivaNova USA, Inc. $105.30 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546668
Principal investigator 1 LivaNova USA, Inc. $105.30 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546672
Principal investigator 1 LivaNova USA, Inc. $105.30 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546676
Principal investigator 1 LivaNova USA, Inc. $1,210.95 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546681
Principal investigator 1 LivaNova USA, Inc. $1,124.55 06/10/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546686
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 06/02/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332680
Principal investigator 1 Janssen Research & Development, LLC $4,472.00 05/29/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332595
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $235.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347952
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,678.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347954
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,353.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347956
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,353.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347958
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,124.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347988
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $92.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347990
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $48.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347992
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $99.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347994
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $99.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347996
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $99.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242347998
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $137.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242348000
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $137.00 05/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242348030
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,150.00 05/20/2025 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP
ACP-103-070 No dispute reported 06/30/2026 1245934237
Principal investigator 1 ACADIA Pharmaceuticals Inc $8,261.89 05/20/2025 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP
ACP-103-069 No dispute reported 06/30/2026 1245934249
Principal investigator 1 LivaNova USA, Inc. $1,210.95 05/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546624
Principal investigator 1 LivaNova USA, Inc. $1,124.55 05/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546629
Principal investigator 1 LivaNova USA, Inc. $105.30 05/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546637
Principal investigator 1 LivaNova USA, Inc. $687.15 05/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546640
Principal investigator 1 LivaNova USA, Inc. $105.30 05/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546694
Principal investigator 1 LivaNova USA, Inc. $105.30 05/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546699
Principal investigator 1 LivaNova USA, Inc. $1,124.55 05/09/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546708
Principal investigator 1 Janssen Research & Development, LLC $3,300.00 05/07/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214438
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,000.00 05/02/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242345717
Principal investigator 1 PFIZER INC. $7,788.35 04/24/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228853740
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,145.00 04/23/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242343981
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $103.00 04/23/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242343991
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,353.00 04/23/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242343993
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,353.00 04/23/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242343995
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,486.00 04/23/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242343997
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $44.00 04/23/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
ITI-007-602 No dispute reported 06/30/2026 1242343999
Principal investigator 1 Janssen Research & Development, LLC $3,300.00 04/09/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214412
Principal investigator 1 LivaNova USA, Inc. $750.60 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546602
Principal investigator 1 LivaNova USA, Inc. $1,210.95 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546605
Principal investigator 1 LivaNova USA, Inc. $1,124.55 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546610
Principal investigator 1 LivaNova USA, Inc. $105.30 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546614
Principal investigator 1 LivaNova USA, Inc. $687.15 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546620
Principal investigator 1 LivaNova USA, Inc. $687.15 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546691
Principal investigator 1 LivaNova USA, Inc. $687.15 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546702
Principal investigator 1 LivaNova USA, Inc. $105.30 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546712
Principal investigator 1 LivaNova USA, Inc. $105.30 04/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546714
Principal investigator 1 PFIZER INC. $71.83 04/04/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228853770
Principal investigator 1 Janssen Research & Development, LLC $1,735.00 03/28/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332665
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 03/20/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332700
Principal investigator 1 Janssen Research & Development, LLC $39.72 03/13/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332742
Principal investigator 1 Janssen Research & Development, LLC $1,775.00 03/12/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214391
Principal investigator 1 LivaNova USA, Inc. $1,210.95 03/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546584
Principal investigator 1 LivaNova USA, Inc. $1,124.55 03/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546588
Principal investigator 1 LivaNova USA, Inc. $105.30 03/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546595
Principal investigator 1 LivaNova USA, Inc. $687.15 03/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546598
Principal investigator 1 LivaNova USA, Inc. $1,210.95 03/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546796
Principal investigator 1 LivaNova USA, Inc. $1,210.95 03/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546801
Principal investigator 1 LivaNova USA, Inc. $105.30 03/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546807
Principal investigator 1 LivaNova USA, Inc. $687.15 03/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546815
Principal investigator 1 Janssen Research & Development, LLC $8,209.00 03/03/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332737
Principal investigator 1 PFIZER INC. $2,539.86 02/27/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228859856
Principal investigator 1 LivaNova USA, Inc. $687.15 02/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546544
Principal investigator 1 LivaNova USA, Inc. $687.15 02/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546548
Principal investigator 1 Janssen Research & Development, LLC $672.00 02/07/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214418
Principal investigator 1 Janssen Research & Development, LLC $1,538.00 02/03/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332589
Principal investigator 1 PFIZER INC. $7,665.31 01/23/2025 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228859833
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,163.46 01/21/2025 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1245933377
Principal investigator 1 Janssen Research & Development, LLC $1,798.00 01/17/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332649
Principal investigator 1 Janssen Research & Development, LLC $3,800.00 01/15/2025 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175214400
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546524
Principal investigator 1 LivaNova USA, Inc. $750.60 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546527
Principal investigator 1 LivaNova USA, Inc. $1,124.55 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546532
Principal investigator 1 LivaNova USA, Inc. $105.30 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546536
Principal investigator 1 LivaNova USA, Inc. $687.15 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546539
Principal investigator 1 LivaNova USA, Inc. $105.30 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546552
Principal investigator 1 LivaNova USA, Inc. $105.30 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546557
Principal investigator 1 LivaNova USA, Inc. $105.30 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546560
Principal investigator 1 LivaNova USA, Inc. $105.30 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546565
Principal investigator 1 LivaNova USA, Inc. $1,124.55 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546568
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546573
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546577
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/08/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1245546580
Principal investigator 1 LivaNova USA, Inc. $330.00 01/07/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1245556540
Principal investigator 1 LivaNova USA, Inc. $330.00 01/07/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1245557130
Principal investigator 1 ACADIA Pharmaceuticals Inc $332.17 01/06/2025 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP
ACP-103-070 No dispute reported 06/30/2026 1245933133
Principal investigator 1 Janssen Research & Development, LLC $8,344.00 01/06/2025 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175332673